INNOVENT BIOLOGICS INC Action · KYG4818G1010 · A2N7N8 (XHKG) — cotations en temps réel, données d'entreprise, dividendes, fondamentaux et analyse de portefeuille IA sur MoneyPeak

Aperçu

Analyse alimentée par l’IA

Analyse fondamentale

Découvrez ce que disent vraiment les chiffres — avant le marché

Analyser maintenant

Sentiment des actualités

Les actualités d’aujourd’hui sont-elles un signal d’achat ou un avertissement ?

Analyser maintenant

Acheter / Conserver / Vendre

Faut-il acheter, conserver ou vendre ? Obtenez l’avis de l’IA dès maintenant.

Analyser maintenant

Évaluation des risques

Détectez les risques cachés avant qu’ils n’impactent votre portefeuille.

Analyser maintenant

Juste valeur

Cette action est-elle bon marché, correctement valorisée ou surévaluée ?

Analyser maintenant

Dernières analyses d’IA sur INNOVENT BIOLOGICS INC

Pas de cours

30.04.2026 20:00

Cours actuels de INNOVENT BIOLOGICS INC

Bourse	Ticker	Devise	Dernier échange	Cours	Variation journalière
UTC	IVBXF	USD	30.04.2026 20:00	11,25 USD	0,17 USD +1,56 %
Düsseldorf	IBIRSN10.DUSB	EUR	30.04.2026 17:30	9,81 EUR	-
Quotrix	IBIRSN10.DUSD	EUR	30.04.2026 14:56	10,10 EUR	-
Hamburg	IBIRSN10.HAMB	EUR	30.04.2026 06:07	9,75 EUR	-

Fonds investis

Les fonds suivants ont investi dans INNOVENT BIOLOGICS INC :

Fonds iShares MSCI China UCITS ETF USD (Dist)	Vol. en millions 11,06	Part (%) 0,34 %
Fonds iShares MSCI AC Far East ex-Japan UCITS ETF USD (Acc)	Vol. en millions 32,65	Part (%) 0,15 %
Fonds iShares MSCI EM IMI ESG Screened UCITS ETF USD (Dist)	Vol. en millions 342,28	Part (%) 0,11 %
Fonds iShares MSCI EM IMI ESG Screened UCITS ETF USD (Acc)	Vol. en millions 1.732,75	Part (%) 0,11 %
Fonds iShares MSCI EM ESG Enhanced UCITS ETF USD (Acc)	Vol. en millions 699,31	Part (%) 0,06 %

Profil de l'entreprise pour INNOVENT BIOLOGICS INC Action

Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.